{
    "clinical_study": {
        "@rank": "107767", 
        "arm_group": [
            {
                "arm_group_label": "Ruxolitinib plus capecitabine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo plus capecitabine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine\n      for the treatment of metastatic pancreatic cancer."
        }, 
        "brief_title": "A Study of Ruxolitinib in Pancreatic Cancer Patients", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Pancreatic Adenocarcinoma That is Recurrent", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blinded, placebo-controlled, Phase 3 study, in which\n      approximately 270 subjects with advanced or metastatic adenocarcinoma of the pancreas who\n      have failed or were intolerant to first-line chemotherapy will be randomized (1:1) to one of\n      the following treatment groups:\n\n        -  Treatment A (N = 135):  Capecitabine 2000 mg/m^2 daily (1000 mg/m^2 twice daily [BID])\n           + ruxolitinib 15 mg BID\n\n        -  Treatment B (N = 135):  Capecitabine 2000 mg/m^2 daily (1000 mg/m^2 BID) + placebo\n           (administered BID)\n\n      Treatment will consist of repeating 21-day cycles.  Capecitabine will be self-administered\n      for the first 14 days of each cycle, and ruxolitinib/placebo will be self-administered\n      during the entire cycle.  Treatment for all subjects will continue as long as the regimen is\n      tolerated, and the subject does not meet discontinuation criteria.  Subjects who discontinue\n      treatment will continue to be followed for subsequent anticancer treatments and survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas.\n\n          -  Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Received 1 prior chemotherapy regimen for advanced or metastatic disease (not\n             including neoadjuvant and/or adjuvant therapy).\n\n          -  \u2265 2 weeks elapsed from the completion of previous treatment regimen and subjects must\n             have recovered or be at a new stable baseline from any related toxicities.\n\n          -  Radiographically measurable or evaluable disease\n\n        Exclusion Criteria:\n\n          -  Received more than 1 prior chemotherapy regimen for advanced or metastatic disease.\n\n          -  Ongoing radiation therapy, radiation therapy administered within 30 days of\n             enrollment, or prior history of radiation therapy to \u2265 25% of the bone marrow.\n\n          -  Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery,\n             immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor\n             embolization).\n\n          -  Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase\n             deficiency (DPD), or other known sensitivity to fluorouracil (5-FU)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119663", 
            "org_study_id": "INCB 18424-363"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ruxolitinib plus capecitabine", 
                "description": "5 mg tablets to be administered by mouth\n15 mg BID", 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Jakafi \u00ae", 
                    "Jakavi \u00ae"
                ]
            }, 
            {
                "arm_group_label": "Placebo plus capecitabine", 
                "description": "5 mg matching placebo tablets to be administered by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ruxolitinib plus capecitabine", 
                    "Placebo plus capecitabine"
                ], 
                "description": "Capecitabine 2000 mg/m^2 daily (1000 mg/m^2 twice daily [BID])", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Metastatic pancreatic cancer", 
        "lastchanged_date": "April 17, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)", 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Albert Assad, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "Randomization until death due to any cause. Approximately 27 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Randomization to disease progression, or death due to any cause if sooner. Approximately 27 months."
            }, 
            {
                "description": "Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment", 
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study. Approximately 27 months."
            }, 
            {
                "description": "Duration of response determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study. Approximately 27 months."
            }, 
            {
                "measure": "Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through approximately 30 days post treatment discontinuation. Approximately 27 months"
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}